News

C&EN23d
The Scientific Method as a Scaffold to Enhance Communication Skills in Chemistry
The format taught is consistent with the guidelines provided by the American Chemical Society (ACS). (63,64) Overall, students (1) gain a deeper appreciation for the scientific method through ...
SciELO29d
Mechanism of action of sodium hypochlorite - SciELO
Oral Surg Oral Med Oral Path 1994;78:522-530. 2. Nair PNR. Apical periodontites: a dynamic encounter between root canal infection and host response. Periodontol 2000;1997:13:121-48. 3. Byströn A, ...
WOOD-TV29d
2025 ASCO Oral Presentation: Innovent Biologics Announces Updated Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) from the ... - WOODTV.com
Among the patients with PD-L1 TPS<1%, IBI363 demonstrated outstanding efficacy signals: in the 1/1.5 mg/kg group (N=10), the confirmed ORR was 30.0% and the DCR was 90.0%, while that of the 3 mg ...
PipelineReview.com29d
2025 ASCO Oral Presentation: Innovent Biologics Announces Updated Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) from the Phase 1 PoC ...
SAN FRANCISCO, CA, USA and SUZHOU, China I June 3, 2025 I Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes ...
Yahoo Finance1mon
2025 ASCO Oral Presentation: Innovent Biologics Announces Updated Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) from the Phase 1 PoC ...
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology ...
KTLA1mon
2025 ASCO ｜Oral Presentation: Disitamab Vedotin Achieves Stellar Efficacy as First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic Gastric Cancer
YANTAI, China, June 2, 2025 /PRNewswire/ -- On June 2 (Chicago time), i n an oral presentation at the 2025 ASCO Annual Meeting, Dr. Lin Shen from Beijing Cancer Hospital presented the results of a ...
Nasdaq1mon
2025 ASCO ｜Oral Presentation: Disitamab Vedotin Achieves Stellar Efficacy as First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic Gastric Cancer - Nasdaq
--On June 2, i n an oral presentation at the 2025 ASCO Annual Meeting, Dr. Lin Shen from Beijing Cancer Hospital presented the results of a Phase 2 clinical study conducted in China evaluating the ...
Yahoo Finance1mon
2025 ASCO Oral Presentation: Innovent Biologics Announces Updated Date of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) from Phase 1 Clinical ...
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, ...
KTLA1mon
2025 ASCO Oral Presentation: Innovent Biologics Announces Updated Date of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) from Phase 1 Clinical ...
SAN FRANCISCO, and SUZHOU, China, June 1, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...
The Victoria Advocate1mon
BIAL Announces Oral Presentation at GBA1 Meeting 2025
Presentation Details: Date and Time: June 5, 2025; 12:00-12:20 PM Session: Small molecules targeting GBA1 - session 2 Presenter: Raquel Costa, Senior Manager, Clinical Operations, BIAL ...
The Victoria Advocate1mon
BIAL Announces Oral Presentation at GBA1 Meeting 2025
PORTO, Portugal, June 2, 2025 /PRNewswire/ -- BIAL, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, today announced that it will give an oral ...